title: Symmetrical onychomadesis in Norwegian Gordon and English setters.
abstract: This study reports the condition onychomadesis affecting multiple claws in Norwegian Gordon and English setters. Medical records of and claw biopsies from 18 Gordon and four English setters with onychomadesis of multiple claws were obtained from July 2005 to January 2007. Only dogs with symmetrical onychomadesis and no signs of concurrent disease were included. Histopathological features varied between dogs, but typically included interface dermatitis with subepidermal cleft formation, pigment incontinence, basal cell vacuolization and necrosis, spongiosis and lymphocytic exocytosis, a lymphocytic, plasmacytic subepidermal inflammation, and fibroplasia. In two dogs, histopathological signs of a superficial infection were present. The age of onset of disease varied between 2 and 7 years with a mean of 3.9 years, and was not correlated with vaccination time. Six of the affected dogs also had siblings with the disease. Due to the close relationship of the affected dogs, pedigree map analysis was not possible. Three dogs were euthanized because of the disease and two had regrowth of normal claws. Seventeen dogs had persistent onychodystrophy that typically was nonpainful during therapy which in most dogs consisted of fatty acid supplementation or prednisolone.
authors.affiliation: Fredrikstad Animal Hospital, Fredrikstad, Norway.
authors.forename: Martine L
authors.initials: ML
authors.lastname: Ziener
authors.forename: Sonya V
authors.initials: SV
authors.lastname: Bettenay
authors.forename: Ralf S
authors.initials: RS
authors.lastname: Mueller
mesh_terms: D017668:Age of Onset; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D004285:Dogs; D005227:Fatty Acids / Q000627:therapeutic use; D005260:Female; D006724:Hoof and Claw / Q000473:pathology; D008297:Male; D009264:Nails, Malformed / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000662:veterinary*; D010375:Pedigree; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005227:Fatty Acids; D011239:Prednisolone